Several prior groups have sought to address this question with some cohorts reporting BRAF and KRAS mutations to be more common in CRC seen in patients with later age of diagnosis which is particularly relevant given the implications of these mutations for targeted therapies (4–8). The gene discussed is BRAF; the disease is colorectal carcinoma.